
The Future of Anesthetic Pharmacology

Steven L. Shafer, MD

There have been few, if any, significant new drugs introduced into the practice of anesthesiology in the last 10 years. Look at when the Food and Drug Administration approved our “new” drugs (Table 1):

This lack of progress does not reflect a lack of unmet medical needs. If we examine the three classes of drugs typically associated with anesthesia practice, we find significant problems with the present armamentarium.

There are numerous problems with the available hypnotics. The inhaled anesthetics, as a class, appear to be pronociceptive at low concentrations (1–3), potentially increasing postoperative pain. Propofol stings on injection, despite the various tricks used to attenuate this brief, but intense, pain (4,5). Propofol infusions are associated with acidosis and multiorgan failure in children (6) and occasionally in adults (7). Thiopental is unsuitable for maintenance because of accumulation. Etomidate for induction causes myoclonus, and maintenance of anesthesia results in adrenal suppression (8,9).

Our available analgesics are limited to opioids, ketamine, and nonsteroidal antiinflammatory drugs (NSAIDs). The opioids share the common side effects of ventilatory depression, ileus, sedation, pruritus, urinary retention, and addictive potential. Ketamine causes psychosis. The nonselective NSAIDs are associated with increased risk of bleeding and may delay bone healing, whereas the cyclooxygenase (COX)-2 selective NSAIDs are prothrombotic (10).

As to muscle relaxants, we still do not have a replacement for succinylcholine. Rapacuronium showed promise when it was approved in 1999, but it lasted on the market for less than 1 year because it causes severe bronchoconstriction (11) by an unusual action on M_3 muscarinic receptors (12). In fact, the last exciting development in muscle relaxants was when vecuronium went generic in 1995.

The good news is that we are not an orphaned specialty. There are exciting, new pharmaceuticals in the pipeline that may profoundly change the practice of anesthesia over the next decade. I will quickly summarize information that is publicly available about these. By way of disclosure, I have consulted to Alza,

Amphastar, AstraZeneca, Delex, Durect, Endo, Glaxo, Guilford, Painceptor, and Theravance, whose products are mentioned below.

Hypnotics

A number of companies are working on alternative formulations for propofol (13). The primary goals are to remove or alter the lipid, which may be associated with propofol syndrome. The “Diprivan” formulation of propofol, the original product from AstraZeneca, is a mixture of propofol in Intralipid, a mixture of long-chain triglycerides. Intralipid may cause dysfunction of the reticuloendothelial system (14,15). Furthermore, the pain on injection with propofol is associated with the free fraction, (16,17) and modifications of the formulation can potentially reduce the free propofol concentration (18).

The Braun Corporation introduced the “Lipuro” formulation emulsifying propofol in medium- and long-chain triglycerides. The Lipuro formulation does not alter the pharmacokinetics of propofol (16), but it is associated with less pain on injection (19,20). Triglyceride chain length influences how triglycerides affect the immune system (21), and the medium-chain triglyceride formulations have been shown to be beneficial *in vitro* (22). However, I could not find any studies suggesting that use of the medium-chain formulation of propofol had any beneficial effects on the immune system when compared with the original Diprivan formulation.

Another medium-chain triglyceride propofol formulation is IDD-D propofol, developed by RTP Pharma, a Canadian company. This is a 2% formulation, twice the concentration of propofol found in Diprivan. Although it reduces the lipid load (as would be expected, because it is twice as much propofol per cc of lipid vehicle) (23), it is associated with increased pain on injection and, interestingly, a slower onset of drug effect than Diprivan (24). Increased pain on injection has also been reported for the “Ampofol” low-fat propofol formulation developed by Amphastar (25,26).

Table 1.

- Desflurane → 1992
- Mivacurium → 1992
- Rocuronium → 1994
- Cisatracurium → 1995
- Sevoflurane → 1995
- Remifentanyl → 1996
- Dexmedetomidine → 1999
- Since then → Nothing!

Cyclodextrins are water-soluble cyclic carbohydrates. As shown in Figure 1 they contain a hydrophobic cavity that can accommodate a lipid-soluble drug molecule (27). Egan and colleagues documented equivalent propofol pharmacokinetics and pharmacodynamics with a sulfobutyl ether- β -cyclodextrin and Diprivan (28,29).

Another option being explored for propofol delivery is micelles, as shown in Figure 2. These micelles are small, which makes formulations of propofol in micelles visually clear (30). Maelor, a UK pharmaceutical company, has developed a micellar formulation of propofol that is apparently associated with increased pain on injection (31). A clear formulation of propofol, Cleofol, has recently been introduced in India by Themis Medicare. The clear appearance suggests that the propofol is emulsified in micelles, although the manufacturer has not disclosed the preparation. This formulation is associated with an 89% incidence of severe pain on injection (32), as well as damage to infusion sets (33) and veins (34). In fact, this formulation is so problematic that one group of investigators concluded that the Cleofol propofol formulation "should only be used for patients who demand a pure vegetarian induction agent" (35).

Finally, Guilford Pharmaceuticals has been pursuing development of water-soluble prodrug of propofol, termed "Aquavan" (36,37). As shown in Figure 3, Aquavan is a phosphate-linked propofol prodrug that releases phosphate and formaldehyde on hydrolysis. The propofol concentration peaks approximately 8 min after an injection of Aquavan (38). Almost all subjects receiving Aquavan report a paresthesia on injection (39) that has been described as "a transient unpleasant sensation of burning or tingling of moderate severity in the anal and genital region" (40). The slow onset of sedation with Aquavan renders it unsuitable to replace propofol as an anesthetic induction agent. Aquavan is now being developed by MGI Pharma for procedural sedation.

A truly novel hypnotic is currently in development at Theravance Corporation. This compound has been described only in abstracts (41–43). Figure 4 shows the offset of drug effect in rats after Diprivan infusions of 20 min, 3 h, and 7 h (left bars), and THRX-918661 (right bars). No available data suggests that this drug has advanced to clinical trials, but a hypnotic with




Figure 1. Cyclodextrins, water-soluble cyclic carbohydrates, contain a hydrophobic cavity that can accommodate a lipid-soluble drug molecule. From Baker and Naguib (13).




Figure 2. Micelles. From Baker and Naguib (13).




Figure 3. Aquavan, a water-soluble prodrug of propofol. From Gibiansky et al. (38).

ultra-rapid metabolism could revolutionize anesthetic practice as much as Diprivan did 20 years ago.

Xenon continues to be explored for its hypnotic properties, and one company, Protexon, is currently developing xenon for commercial use (44). Xenon has potent analgesic properties (45,46). However, much of the current interest in xenon is based on its neuroprotective properties (47–49). Xenon has been shown to




Figure 4. Offset of drug effect in rats after Diprivan infusions of 20 min, 3 h, and 7 h (left bars), and THR-918661 (right bars). From Beattie et al. (41).

produce more rapid recovery than isoflurane, with a favorable cardiovascular and respiratory profile (50). The primary obstacle towards use of xenon is the high cost, estimated to be approximately \$160 for a 4-h anesthetic (51). The cost is not astronomical, given that xenon comes close to being an “ideal” inhaled anesthetic, but the cost has precluded any company from bringing xenon to market.

Melatonin and melatonin analogs possess hypnotic properties when injected IV, comparable to the properties of propofol and thiopental, at least in rats (52). The electroencephalographic (EEG) effects of IV melatonin resemble the effects of thiopental and propofol (53). The melatonin analog 2-bromomelatonin is more potent than melatonin. It also renders rats unconscious, with rapid onset and recovery, similar to that observed with propofol (54). Low concentrations of 2-bromomelatonin also appear to be analgesic in rats, unlike propofol, which has no analgesic properties. To date no human data exist on the use of melatonin to induce or maintain anesthesia.

Muscle Relaxants

The drug shown in Figure 5 is GW280430A, and asymmetric mixed-onium chlorofumarates, currently under development by GlaxoSmithKline (55,56). This is a novel structure for a muscle relaxant, although it has many similarities to mivacurium. GW280430A undergoes metabolism in the plasma by alkaline hydrolysis and, apparently more significantly, spontaneous formation of cysteine adducts, deactivating the molecule (57). Because this is a spontaneous reaction in blood, it does not depend on any catalytic activity and thus should be associated with very little genetic variability in the population.

The onset of action of GW280430A is only slightly slower than succinylcholine. In human studies, peak effect at a dose of 0.18 mg/kg (ED₉₅) ranges from 2.3 to 3 min, with recovery in approximately 10 min (56). Increasing the dose to 0.54 mg/kg (three times the ED₉₅) hastens the onset time to 1.2 to 1.8 min and




Figure 5. GW280430A, and asymmetric mixed-onium chlorofumarates. From Savarese et al. (55).

increases block duration to approximately 15 min. Higher doses cause the release of histamine, similar to mivacurium, without significantly enhancing the rate of onset. GW280430A comes the closest to a true succinylcholine replacement of any nondepolarizing muscle relaxant to date.

The other exciting development for muscle relaxants is sugammadex, a name as novel as the compound. Sugammadex is a cyclodextrin specifically designed to bind rocuronium (58). Shown in Figure 6, sugammadex has a pocket that specifically binds rocuronium (59). By binding the available rocuronium, sugammadex rapidly and completely reverses neuromuscular blockade, even in the presence of an ongoing infusion of rocuronium. In human studies, sugammadex 8.0 mg/kg reversed neuromuscular blockade within 1 min of administration, without any apparent toxicity (60). If sugammadex does not have some as-yet unappreciated toxicity, it will render conventional pharmacological reversal of neuromuscular blockade obsolete. Patients will no longer be exposed to the nausea-inducing properties of neostigmine, on the tachycardic effects of atropine and glycopyrrolate. Moreover, imperfect titration of a muscle relaxant occasionally creates a block that cannot be readily reversed at the conclusion of anesthesia. This will no longer be an issue with sugammadex, as even profound neuromuscular blockade can be readily reversed by giving an adequate dose of sugammadex.

Analgesics

Analgesics are perhaps the most exciting area of pharmaceutical development related to the practice of anesthesia. This review will cover new developments in opioid pharmacology, followed by a discussion of other centrally acting analgesics, and conclude on the subject of peripherally acting analgesics.

Opioids. Perhaps the most remarkable change in analgesics in the past 10 years has been the morphing of fentanyl from an esoteric IV analgesic exclusively




Figure 6. Sugammadex, a cyclodextrin specifically designed to bind rocuronium. From Epemolu et al. (59).

used by anesthesiologists to a drug commonly used for many kinds of chronic pain. This has been accomplished through the introduction of transdermal fentanyl for cancer pain, and the subsequent introduction of oral transmucosal fentanyl citrate for “break-through pain” in cancer patients. Duragesic sales were \$1.2 billion in 2004, making it one of the most commercially successful analgesics ever introduced. Actiq sales in 2005 were expected to exceed \$400 million. Cephalon, the company that sells Actiq, is now working on a rapidly dissolving sublingual fentanyl tablet called “Oravescent,” which provides more rapid onset than the oral transmucosal fentanyl delivery system (61).

Pharmaceutical companies continue to innovate with fentanyl delivery systems. Alza recently received approval for “E-trans” fentanyl, a transdermal iontophoretic fentanyl delivery system. As shown in Figure 7, pain relief with the E-trans fentanyl delivery system was comparable to that of patient-controlled analgesia (PCA) morphine for postoperative analgesia (62).

Another route of fentanyl delivery is through the lungs. Inhaled free fentanyl has a rapid peak and offset, resembling IV administered fentanyl (63). However, the rate of onset and the duration of effect can be modulated by encapsulating inhaled fentanyl in liposomes (64), an approach being explored by Delex pharmaceuticals.

Sufentanil is also being adapted to the needs of patients with chronic pain. Durect, an Alza spinoff, is developing a system to deliver systemic sufentanil over a period of months with an injectable osmotic pump (65). The device, shown in Figure 8, is approximately the size of a matchstick. Because sufentanil is highly potent, this one device can potentially deliver 3 to 6 mo of sufentanil to a patient with chronic, unrelenting pain.

Morphine is another old analgesic that has been reintroduced recently with a novel delivery system. In




Figure 7. Pain relief with the E-trans fentanyl delivery system was comparable to that of patient-controlled analgesia (PCA) morphine for postoperative analgesia. From Viscusi et al. (62).




Figure 8. Injectable osmotic pump developed by Durect to deliver systemic sufentanil over a period of months. From www.durect.com.

2004 Endo Pharmaceutical introduced “DepoDur,” epidural morphine in a liposomal formulation. A single epidural injection provides up to 2 days of effective analgesia after hip replacement surgery (66). This formulation of extended-release morphine has also proven effective after cesarean delivery (67) and abdominal surgery (68).

Morphine-6-glucuronide is another “old” analgesic. However, this active metabolite of morphine has never been introduced into clinical practice. Nevertheless, it is currently being developed for postoperative analgesia by CeNeS Pharmaceuticals. Studies suggest that morphine-6-glucuronide causes less ventilatory depression per an equipotent analgesic dose than morphine in human volunteers (69). It may also have activity in peripheral antinociception (70).

Finally, there are exciting developments in drugs that antagonize opioid side effects. Two drugs are very near Food and Drug Administration approval, alvimopan from Adolor and methyl naltrexone from Progenics. Alvimopan, the “Molecule of the Month” in June 2005 (71), is an orally delivered μ -opioid antagonist to prevent opioid-induced ileus (72). It has very little systemic absorption, and it does not cross the

blood-brain barrier. It effectively reverses opioid-induced ileus (73). Methylnaltrexone is absorbed systemically after oral delivery but does not cross the blood-brain barrier. It is being developed for oral, IV, and subcutaneous delivery. It also effectively reverses ileus, and it is exceedingly well tolerated (74).

In a landmark study, Manzke (an anesthesiology resident at the time) and colleagues identified the role of 5HT_{4(a)} agonists on opioid-induced ventilatory depression (75). Specifically, a Novartis 5HT_{4(a)} agonist, BIMU8, selectively reversed fentanyl-induced ventilatory depression, without affecting analgesic response in rats. This creates the possibility that opioids could be co-formulated with 5HT_{4(a)} agonists, preventing opioid-induced ventilatory depression.

Other Centrally Acting Analgesics. Melatonin possesses analgesic activity that is reversed by naloxone (76). Recent studies suggest that the analgesic activity of melatonin is related to the release of β -endorphin (77). Melatonin also has anti-inflammatory properties that may contribute to its analgesic effects (78).

Cannabinoids are also a potentially important new class of analgesics. Dronabinol is a synthetic δ -9-tetrahydrocannabinol that has demonstrated analgesia in patients with multiple sclerosis (79). However, the use of dronabinol is limited by dizziness and other central effects. Ajulemic acid is a novel cannabinoid with no psychotropic effects (80). It has been shown to be effective in chronic neuropathic pain (81,82).

Peripherally Acting Analgesics. Peripheral kappa opioid agonists continue to be pursued as analgesic targets (83). There is evidence that peripheral kappa agonists can be effective analgesics (84,85). Adolor Corporation continues to explore peripheral δ opioid agonists as well.

Many peripheral opioids act through the "Transient Receptor Potential V1" (aka VR1 and TRPV1) ion channel. This channel, located mostly on C fibers in the periphery, is sensitive to capsaicin, acid, heat, and some lipids. Opening this channel permits the influx of calcium, triggering an action potential.

Calcium is toxic to C fibers in high doses. Capsaicin can hold this channel open long enough to permit enough calcium to enter to cause the C fiber to become non-functional. This is the basis of capsaicin use for chronic pain (86). Resiniferatoxin permits enough calcium to enter that the C fiber is permanently destroyed, providing long-term analgesia through selective chemical ablation of C fibers (87–89). Resiniferatoxin is another potentially revolutionary development in anesthetic pharmacology, particularly in the treatment of severe chronic pain in terminally ill patients.

Acid causes pain both through TRPV1 receptors as well as through specific, acid-sensing ion channels (90). The "ASIC" channels blocked by the diuretic

amiloride are promising candidates for analgesic development (91). Painceptor, a Canadian company, currently has identified candidate ASIC antagonists.

Conclusion

After a decade of relatively sparse pharmaceutical industry interest in anesthetic drugs, we are now posed to see dramatic developments in the three major classes of drugs primarily associated with our specialty: hypnotics, muscle relaxants, and analgesics. Of these, the analgesic pipeline has the most candidates, and it addresses the largest unmet medical need of our specialty.

References

1. Zhang Y, Eger EI II, Dutton RC, Sonner JM. Inhaled anesthetics have hyperalgesic effects at 0.1 minimum alveolar anesthetic concentration. *Anesth Analg* 2000;91:462–6.
2. Kingery WS, Agashe GS, Guo TZ, et al. Isoflurane and nociception: spinal alpha2A adrenoceptors mediate antinociception while supraspinal alpha1 adrenoceptors mediate pronociception. *Anesthesiology* 2002;96:367–74.
3. Rowley TJ, Daniel D, Flood P. The role of adrenergic and cholinergic transmission in volatile anesthetic-induced pain enhancement. *Anesth Analg* 2005;100:991–5.
4. Maleck WH, Piper SN, Roehm KD. Propofol-induced injection pain: comparison of a modified propofol emulsion and standard propofol with premixed lidocaine. *Anesth Analg*. 2005;100:1858.
5. Shimizu T, Inomata S, Kihara S, et al. Rapid injection reduces pain on injection with propofol. *Eur J Anaesthesiol* 2005;22:394–6.
6. Okamoto MP, Kawaguchi DL, Amin AN. Evaluation of propofol infusion syndrome in pediatric intensive care. *Am J Health Syst Pharm* 2003;60:2007–14.
7. Liolios A, Guerit JM, Scholtes JL, et al. Propofol infusion syndrome associated with short-term large-dose infusion during surgical anesthesia in an adult. *Anesth Analg* 2005;100:1804–6.
8. Fellows IW, Bastow MD, Byrne AJ, Allison SP. Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. *BMJ* 1983;17:287(6408):1835–7.
9. Wagner RL, White PF, Kan PB, et al. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. *N Engl J Med* 1984;310:1415–21.
10. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. *N Engl J Med* 2005;352:1081–91.
11. Fine GF, Motoyama EK, Brandom BW, et al. The effect on lung mechanics in anesthetized children with rapacuronium: a comparative study with mivacurium. *Anesth Analg*. 2002;95:56–61.
12. Jooste EH, Sharma A, Zhang Y, Emala CW. Rapacuronium augments acetylcholine-induced bronchoconstriction via positive allosteric interactions at the M3 muscarinic receptor. *Anesthesiology* 2005;103:1195–203.
13. Baker MT, Naguib M. Propofol: the challenges of formulation. *Anesthesiology* 2005;103:860–76.
14. Kelbel I, Koch T, Weber A, et al. Alterations of bacterial clearance induced by propofol. *Acta Anaesthesiol Scand* 1999;43:71–6.
15. Furukawa K, Yamamori H, Takagi K, et al. Influences of soybean oil emulsion on stress response and cell-mediated immune function in moderately or severely stressed patients. *Nutrition* 2002;18:235–40.
16. Doenicke AW, Roizen MF, Rau J, et al. Pharmacokinetics and pharmacodynamics of propofol in a new solvent. *Anesth Analg* 1997;85:1399–403.

17. Ohmizo H, Obara S, Iwama H. Mechanism of injection pain with long and long-medium chain triglyceride emulsive propofol. *Can J Anaesth* 2005;52:595–9.
18. Yamakage M, Iwasaki S, Satoh J, Namiki A. Changes in concentrations of free propofol by modification of the solution. *Anesth Analg* 2005;101:385–8.
19. Rau J, Roizen MF, Doenicke AW, et al. Propofol in an emulsion of long- and medium-chain triglycerides: the effect on pain. *Anesth Analg* 2001;93:382–4.
20. Dubey PK, Kumar A. Pain on injection of lipid-free propofol and propofol emulsion containing medium-chain triglyceride: a comparative study. *Anesth Analg* 2005;101:1060–2.
21. Wanten GJ, Geijtenbeek TB, Raymakers RA, et al. Medium-chain, triglyceride-containing lipid emulsions increase human neutrophil beta2 integrin expression, adhesion, and degranulation. *J Parenter Enteral Nutr* 2000;24:228–33.
22. Heine J, Jaeger K, Weingaertner N, et al. Effects of different preparations of propofol, diazepam, and etomidate on human neutrophils in vitro. *Acta Anaesthesiol Scand* 2001;45:213–20.
23. Norton JR, Bailey PL, Litman RS, Ward DS. Lower plasma triglyceride levels with a new propofol formulation. *Anesthesiology* 2001;95:A486.
24. Ward DS, Norton JR, Guivarc'h PH, et al. Pharmacodynamics and pharmacokinetics of propofol in a medium-chain triglyceride emulsion. *Anesthesiology* 2002;97:1401–8.
25. Song D, Hama M, White PF, et al. The pharmacodynamic effects of a lower-lipid emulsion of propofol: a comparison with the standard propofol emulsion. *Anesth Analg* 2004;98:687–91.
26. Song D, Hamza MA, White PF, et al. Comparison of a lower-lipid propofol emulsion with the standard emulsion for sedation during monitored anesthesia care. *Anesthesiology* 2004;100:1072–5.
27. Albers E, Muller BW. Cyclodextrin derivatives in pharmaceuticals. *Crit Rev Ther Drug Carrier Syst* 1995;12:311–37.
28. Egan TD, Kern SE, Johnson KB, Pace NL. The pharmacodynamics of propofol in a modified cyclodextrin formulation versus propofol in an intralipid formulation: an electroencephalographic and hemodynamic study in a porcine model. *Anesthesiology* 2001;95:A490.
29. Egan TD, Kern SE, Johnson KB, Pace NL. The pharmacokinetics and pharmacodynamics of propofol in a modified cyclodextrin formulation versus propofol in a lipid formulation: an electroencephalographic and hemodynamic study in a porcine model. *Anesthesiology* 2002;96:A437.
30. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. *Crit Rev Ther Drug Carrier Syst* 2003;20:357–403.
31. Clinically equivalent yet clearly different: micellar solubilisation of propofol. Newbridge, Wrexham, UK: Maelor Pharmaceuticals Ltd. Available at: <http://www.maelor.plc.uk/pdfs/products/poster.pdf>.
32. Dubey PK, Kumar A. Pain on injection of lipid-free propofol and propofol emulsion containing medium-chain triglyceride: a comparative study. *Anesth Analg* 2005;101:1060–2.
33. Puri GD, Singh KP. Damage to the three-way valves by a clear propofol formulation. *Anesth Analg* 2004;98:1193–4.
34. Dubey PK, Kumar A. Vascular complication following lipid free propofol injection. *J Postgrad Med* 2005;51:73–4.
35. Sood D, Tewari A, Katyal S, et al. Pain on injection of cleofol. *Anaesthesia* 2005;60:521–2.
36. Skywalks M, Ihmsen H, Tzabazis A, et al. Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. *Eur J Anaesthesiol* 2003;20:182–90.
37. Krasowski MD. GPI-15715 Guilford. *Curr Opin Investig Drugs* 2005;6:90–8.
38. Gibiansky E, Struys MM, Gibiansky L, et al. AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics. *Anesthesiology* 2005;103:718–29.
39. Gibiansky E, Struys MM, Gibiansky L, et al. AQUAVAN injection, a water-soluble prodrug of propofol, as a bolus injection: a phase I dose-escalation comparison with DIPRIVAN (part 1): pharmacokinetics. *Anesthesiology* 2005;103:718–29.
40. Fechner J, Ihmsen H, Hatterscheid D, et al. Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. *Anesthesiology* 2003;99:303–13.
41. Beattie D, Jenkins T, McCullough J, et al. The *in vivo* activity of THRX-918661, a novel, pharmacokinetically-responsive sedative/hypnotic agent. Presented at the UK SIVA Meeting, Glasgow, May 30–31, 2003. Available at: <http://www.sivauk.org/Glasgow/Abstracts/Beattie.htm>.
42. Jenkins T, Beattie D, Jaw-Tsai S, et al. THRX-918661, a novel, pharmacokinetically-responsive sedative/hypnotic agent. UK SIVA Meeting, Glasgow 2003.
43. Egan TD, Shafer SL, Jenkins TE, et al. Title: The pharmacokinetics and pharmacodynamics of THRX-918661, a novel sedative/hypnotic agent. *Anesthesiology* 2003;99:A516.
44. Sanders RD, Franks NP, Maze M. Xenon: no stranger to anaesthesia. *Br J Anaesth* 2003;91:709–17.
45. Ma D, Sanders RD, Halder S, et al. Xenon exerts age-independent antinociception in Fischer rats. *Anesthesiology* 2004;100:1313–8.
46. Sanders RD, Ma D, Maze M. Xenon: elemental anaesthesia in clinical practice. *Br Med Bull* 2005;71:115–35.
47. Ma D, Wilhelm S, Maze M, Franks NP. Neuroprotective and neurotoxic properties of the 'inert' gas, xenon. *Br J Anaesth* 2002;89:739–46.
48. Ma D, Hossain M, Pettet GK, et al. Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. *J Cereb Blood Flow Metab* 2005 Jul 20; [epub ahead of print].
49. Ma D, Hossain M, Chow A, et al. Xenon and hypothermia combine to provide neuroprotection from neonatal asphyxia. *Ann Neurol* 2005;58:182–93.
50. Rossaint R, Reyle-Hahn M, Schulte Am Esch J, et al. Multicenter randomized comparison of the efficacy and safety of xenon and isoflurane in patients undergoing elective surgery. *Anesthesiology* 2003;98:6–13.
51. Goto T, Nakata Y, Morita S. Will xenon be a stranger or a friend? The cost, benefit, and future of xenon anesthesia. *Anesthesiology* 2003;98:1–2.
52. Naguib M, Hammond DL, Schmid PG 3rd, et al. Pharmacological effects of intravenous melatonin: comparative studies with thiopental and propofol. *Br J Anaesth* 2003;90:504–7.
53. Naguib M, Schmid PG 3rd, Baker MT. The electroencephalographic effects of IV anesthetic doses of melatonin: comparative studies with thiopental and propofol. *Anesth Analg* 2003;97:238–43.
54. Naguib M, Baker MT, Spadoni G, Gregerson M. The hypnotic and analgesic effects of 2-bromomelatonin. *Anesth Analg* 2003;97:763–8.
55. Savarese JJ, Belmont MR, Hashim MA, et al. Preclinical pharmacology of GW280430A (AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium. *Anesthesiology* 2004;100:835–45.
56. Belmont MR, Lien CA, Tjan J, et al. Clinical pharmacology of GW280430A in humans. *Anesthesiology* 2004;100:768–73.
57. Boros EE, Samano V, Ray JA, et al. Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinolinium halofumarates and halosuccinates in rhesus monkeys. *J Med Chem* 2003;46:2502–15.
58. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. *J Med Chem* 2002;45:1806–16.
59. Epemolu O, Bom A, Hope F, Mason R. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. *Anesthesiology* 2003;99:632–7.
60. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. *Anesthesiology* 2005;103:695–703.

61. Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. *Br J Clin Pharmacol* 2005;59:249–53.
62. Viscusi ER, Reynolds L, Chung F, et al. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. *JAMA* 2004;291:1333–41.
63. Mather LE, Woodhouse A, Ward ME, et al. Pulmonary administration of aerosolised fentanyl: pharmacokinetic analysis of systemic delivery. *Br J Clin Pharmacol* 1998;46:37–43.
64. Hung OR, Whyntot SC, Varvel JR, et al. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. *Anesthesiology* 1995;83:277–84.
65. Fisher DM, Kellett N, Lenhardt R. Pharmacokinetics of an implanted osmotic pump delivering sufentanil for the treatment of chronic pain. *Anesthesiology* 2003;99:929–37.
66. Viscusi ER, Martin G, Hartrick CT, et al. Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. *Anesthesiology* 2005;102:1014–22.
67. Carvalho B, Riley E, Cohen SE, et al. Single-dose, sustained-release epidural morphine in the management of postoperative pain after elective cesarean delivery: results of a multicenter randomized controlled study. *Anesth Analg* 2005;100:1150–8.
68. Gambling D, Hughes T, Martin G, et al. A comparison of Depodur, a novel, single-dose extended-release epidural morphine, with standard epidural morphine for pain relief after lower abdominal surgery. *Anesth Analg* 2005;100:1065–74.
69. Romberg R, Olofson E, Sartor E, et al. Pharmacodynamic effect of morphine-6-glucuronide versus morphine on hypoxic and hypercapnic breathing in healthy volunteers. *Anesthesiology* 2003;99:788–98.
70. Tegeder I, Meier S, Burian M, et al. Peripheral opioid analgesia in experimental human pain models. *Brain* 2003;126(Pt 5):1092–102.
71. Molecule of the month. Alvimopan hydrate. *Drug News Perspect*. 2005;18:339–40.
72. Paulson DM, Kennedy DT, Dominick RA, et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction: a 21-day treatment-randomized clinical trial. *J Pain* 2005;6:184–92.
73. Taguchi A, Sharma N, Saleem RM, et al. Selective postoperative inhibition of gastrointestinal opioid receptors. *N Engl J Med* 2001;345:935–40.
74. Yuan CS, Doshan H, Charney MR, et al. J. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. *J Clin Pharmacol* 2005;45:538–46.
75. Manzke T, Guenther U, Ponimaskin EG, et al. 5-HT₄ (a) receptors avert opioid-induced breathing depression without loss of analgesia. *Science* 2003;301(5630):226–9.
76. Yu CX, Zhu B, Xu SF, et al. The analgesic effects of peripheral and central administration of melatonin in rats. *Eur J Pharmacol* 2000;403(1–2):49–53.
77. Shavali S, Ho B, Govitrapong P, et al. Melatonin exerts its analgesic actions not by binding to opioid receptor subtypes but by increasing the release of beta-endorphin an endogenous opioid. *Brain Res Bull* 2005;64:471–9.
78. Mayo JC, Sainz RM, Tan DX, et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. *J Neuroimmunol* 2005;165(1–2):139–49.
79. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. *BMJ* 2004;329(7460):253.
80. Burstein SH, Karst M, Schneider U, Zurier RB. Ajulemic acid: a novel cannabinoid produces analgesia without a “high.” *Life Sci* 2004;75:1513–22.
81. Karst M, Salim K, Burstein S, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. *JAMA* 2003;290:1757–62.
82. Salim K, Schneider U, Burstein S, et al. Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. *Neuropharmacology* 2005;48:1164–71.
83. Kumar V, Guo D, Daubert JD, et al. Amino acid conjugates as kappa opioid receptor agonists. *Bioorg Med Chem Lett* 2005;15:1279–82.
84. Machelska H, Pfluger M, Weber W, et al. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. *J Pharmacol Exp Ther* 1999;290:354–61.
85. Eisenach JC, Carpenter R, Curry R. Analgesia from a peripherally active kappa-opioid receptor agonist in patients with chronic pancreatitis. *Pain* 2003;101:89–95.
86. Sasamura T, Kuraishi Y. Peripheral and central actions of capsaicin and VR1 receptor. *Jpn J Pharmacol* 1999;80:275–80.
87. Kissin I, Bright CA, Bradley EL Jr. Selective and long-lasting neural blockade with resiniferatoxin prevents inflammatory pain hypersensitivity. *Anesth Analg* 2002;94:1253–8.
88. Karai L, Brown DC, Mannes AJ, et al. Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. *J Clin Invest* 2004;113:1344–52.
89. Kissin EY, Freitas CF, Kissin I. The effects of intraarticular resiniferatoxin in experimental knee-joint arthritis. *Anesth Analg* 2005;101:1433–9.
90. Jones NG, Slater R, Cadiou H, et al. Acid-induced pain and its modulation in humans. *J Neurosci* 2004;24:10974–9.
91. Ugawa S, Ueda T, Ishida Y, et al. Amiloride-blockable acid-sensing ion channels are leading acid sensors expressed in human nociceptors. *J Clin Invest* 2002;110:1185–90.